Article info

Download PDFPDF
Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: ‘Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases’ by Giollo et al

Authors

  1. Correspondence to Dr Philip C Robinson, Faculty of Medicine, The University of Queensland, Herston, QLD 4029, Australia; philip.robinson{at}uq.edu.au
View Full Text

Citation

Hyrich KL, Gianfrancesco M, Machado PM, et al
Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: ‘Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases’ by Giollo et al

Publication history

  • Received August 26, 2020
  • Accepted August 27, 2020
  • First published September 7, 2020.
Online issue publication 
August 01, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.